Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem for Injection in Phase Ib Clinical Healthy Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 主要终点
- AUC(0-24) of Benapenem
研究概览
简要总结
To observe the pharmacokinetic profiles of benapenem and its major metabolites in healthy volunteers after continuous multiple-dose benapenem, providing evidence for phase Ⅱ clinical study.
详细描述
A single-center, randomized, open-label, and dose escalation trial design is used in the multiple-dose tolerability and pharmacokinetic studies. The tolerability and pharmacokinetic studies are performed simultaneously. Three doses, 250 mg, 500 mg, and 1000 mg are proposed for multiple-dose tolerability and pharmacokinetic studies. The subjects are divided into two groups, 12 subjects in each group, half males and half females. 250 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed. After completion of observation and confirming that the drug can be safely tolerated, study on 1000 mg group is then performed. Each subject only receives one dose, intravenous drip, once daily, for 7 consecutive days. During the trial, close attention is paid to the tolerability of subjects, and blood samples 4 mL is collected from cubital vein respectively before dosing, 0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 3 h, 5h, 8 h, 12 h, and 24 h after dosing on Day 1 (0 h); before dosing (0 h), 0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 3 h, 5 h, 8 h, 12 h, 24 h, 36 h, and 48 h after dosing on Day 7 for pharmacokinetic study. Blood samples are collected before dosing on Day 4, 5 and 6 to determine the trough concentration for observing the pharmacokinetic profiles of benapenem and its major metabolites in the body after continuous dosing. The next dose group can be studied only when the observation of the previous dose group is completed and it is confirmed that the drug is safely tolerated
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female healthy subjects, aged 18~45;
- •Body weight ≥ 50 kg and body mass index 19.0~24.0 kg/m2;
- •To the test, physical examination, blood routine, urine routine, liver and kidney functions, and related examinations normal, or mild abnormalities in indicators while without clinical significance as indicated by the investigator;
- •Normal or mild abnormalities without clinical significance in the standard 12-lead ECG;
- •Signing informed consent form.
排除标准
- •Regular smoking, alcohol abuse, and drug abuse;
- •Use of drugs with known damage to an organ within three months;
- •History of specific allergies , or history of drug allergy, especially those allergic to lactams and excipients of test drug;
- •Febrile illnesses within three days before the screening;
- •Patients with mental illness or psychotic disorder in the past;
- •Past nervous system diseases (epilepsy, stroke, cerebrovascular disorder, etc.), gastrointestinal disorder (such as stomach ulcers, gastritis, etc.) or disorder of other systems (such as cardiovascular, respiratory, hematological, or endocrine system, etc.) diseases or medical history.
- •Habitually taking any medication, including traditional Chinese medicine;
- •Having taken any medication that may affect test results within two weeks before the screening, such as antibiotics, NSAIDs, aluminum- or magnesium-containing antacids, diuretics, anticoagulants, central nervous system depressants, and any drug that may affect the drug absorption;
- •Having participated in other investigational drug trial in the preceding three months;
- •Blood donation for 360 ml or more within three months before the screening;
- •Heart rate<50bpm or >100bpm; 12)Systolic blood pressure <90 mmHg or ≥140 mmHg, diastolic blood pressure ≥90mmHg or <60mmHg;
- •Women who are pregnant or breastfeeding, or who may be pregnant without adopting acceptable contraception, or who have a positive result in serum pregnancy test;
- •Women who are planning to become pregnant within 6 months, or male subjects who are planning to make his spouse pregnant within 6 months;
- •HBsAg, HCV antibody, HIV antibody, and Treponema pallidum antibody positive;
- •Urine drug-of-abuse testing positive;
- •Any other factor that makes the subject not suitable for the trial as indicated by the investigator.
研究组 & 干预措施
Banapenem C3group
1000mg Once daily for 7
干预措施: Banapenem (Drug)
Banapenem C1 group
250mg Once daily for 7
干预措施: Banapenem (Drug)
Banapenem C2group
500mg Once daily for 7
干预措施: Banapenem (Drug)
结局指标
主要结局
AUC(0-24) of Benapenem
时间窗: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hours after Dosing
AUC(0-24) is the area under the curve from time 0 to 24 hour
Maximum observed plasma concentration (Cmax) of Benapenem
时间窗: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hours after Dosing
Maximum observed plasma concentration (Cmax) of Benapenem in healthy subjects
Time to maximum observed plasma concentration (tmax) of Benapenem
时间窗: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hours after Dosing
Time to maximum observed plasma concentration (tmax) of Benapenem in healthy subjects
Time to elimination half-life (t1/2) of Benapenem
时间窗: Pre dose and 0.25,0.5,0.75,1,1.5, 2, 2.5, 3, 4, 6,8,12, 24hours after Dosing
Time to elimination half-life (t1/2) of Benapenem in healthy subjects
次要结局
- Number of subjects with clinically significant findings in laboratory parameters(Screening, Day1, Day2, Day4 after Dosing)
- Number of subjects with clinically significant 12-lead ECGs(Screening, Day1, Day2, Day4 after Dosing)
- Number of subjects with clinically significant findings in vital signs(Screening, Day1, Day2, Day4 after Dosing)
- Number of subjects with adverse events and serious adverse events(From Screening to Day 4 after dosing)